National Institute of Allergy and Infectious Diseases (NIAID): HIV Infections trials

The registry lists 728 HIV Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 9 are open to participants now and 104 have results posted.

Phase 1 327Phase 2 183Phase 3 57Phase 4 7No phase 195(a study in two phases counts in both)

Studies

Page 8 of 8. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy VolunteersCompletedNCT00000690Phase 1
• Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected IndividualsCompletedNCT00000684Not applicable
• A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusCompletedNCT00000683Phase 1
• A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002CompletedNCT00000682Phase 3
• A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARCCompletedNCT00000680Phase 1
• (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARCCompletedNCT00000679Phase 2
• Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.CompletedNCT00000678Phase 2
• A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine TreatmentCompletedNCT00000671Phase 2
• Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four WeeksCompletedNCT00000670Not applicable
• A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV InfectionCompletedNCT00000669Phase 1
• Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic IndividualsCompletedNCT00000664Phase 1
• A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV DiseaseCompletedNCT00000662Not applicable
• The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected PatientCompletedNCT00000661Phase 1
• A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV DiseaseCompletedNCT00000656Phase 1
• A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZTCompletedNCT00000653Phase 2
• A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV TherapyCompletedNCT00000651Phase 3
• An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected PatientsCompletedNCT00000650Not applicable
• An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV InfectionCompletedNCT00000647Not applicable
• A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 LymphocytesCompletedNCT00000645Phase 1
• A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their NewbornsCompletedNCT00000642Phase 1
• Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000638Not applicable
• A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected ChildrenCompletedNCT00000637Phase 3
• Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000636Not applicable
• A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected ChildrenCompletedNCT00000634Not applicable
• A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59CompletedNCT00000632Phase 1
• The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.CompletedNCT00000629Phase 1
• Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency SyndromeCompletedNCT00000627Not applicable
• A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3CompletedNCT00000625Phase 2